Amylyx Pharmaceuticals (AMLX) Change in Accured Expenses (2021 - 2026)
Amylyx Pharmaceuticals (AMLX) posted quarterly Change in Accured Expenses of -$6.7 million for Q1 2026, up 43.83% year-over-year from -$4.6 million in Q1 2025, and down 452.03% quarter-over-quarter from -$1.2 million in Q4 2025.
Amylyx Pharmaceuticals (AMLX) Change in Accured Expenses (2021 - 2026) Analysis & Trends
Amylyx Pharmaceuticals' Change in Accured Expenses history runs 6 years deep, the most recent figure standing at -$6.7 million for Q1 2026.
- In Q1 2026, Change in Accured Expenses rose 43.83% year-over-year to -$6.7 million; the TTM figure through Mar 2026 stood at -$1.4 million (up 97.83% YoY), while the FY2025 annual figure was -$6.6 million, up 88.97% from the prior year.
- Change in Accured Expenses for Q1 2026 stood at -$6.7 million, down from -$1.2 million in the prior quarter.
- The five-year high for Change in Accured Expenses was $20.8 million in Q4 2023, with the low at -$26.4 million in Q4 2024.
- The 5-year median for Change in Accured Expenses is -$146000.0 (2023), against an average of -$1.5 million.
- The sharpest annual moves came in 2022 and 2024: Change in Accured Expenses jumped 4109.43% in 2022, then tumbled 8879.45% in 2024.
- Amylyx Pharmaceuticals' Change in Accured Expenses stood at $15.6 million in 2022, then jumped by 33.01% to $20.8 million in 2023, then slumped by 227.07% to -$26.4 million in 2024, then soared by 95.42% to -$1.2 million in 2025, then slumped by 452.03% to -$6.7 million in 2026.
- Business Quant data shows AMLX's Change in Accured Expenses at -$6.7 million in Q1 2026, -$1.2 million in Q4 2025, and $1.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.76 Bn | 42.79 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.38 Bn | 39.73 Bn | 2.15 Bn | 82.00 Mn |
| 3 | Zoetis | 31.61 Bn | 29.93 Bn | 1.05 Bn | 142.00 Mn |
| 4 | Takeda Pharmaceutical | 28.64 Bn | 22.84 Bn | 5.10 Bn | -219.00 Mn |
| 5 | United Therapeutics | 22.20 Bn | 19.54 Bn | 683.80 Mn | -4.00 Mn |
| 6 | Viatris | 18.82 Bn | 17.93 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.67 Bn | 15.28 Bn | 935.80 Mn | -8.50 Mn |
| 8 | Elanco Animal Health | 12.11 Bn | 11.58 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.10 Bn | 9.94 Bn | - | - |
| 10 | Amylyx Pharmaceuticals | 4.35 Bn | 4.35 Bn | - | 3.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.18 Mn |
| Jun 30, 2026 | 3.18 Mn |
| Mar 31, 2026 | -6.67 Mn |
| Mar 31, 2026 | -6.67 Mn |
| Dec 31, 2025 | -1.21 Mn |
| Dec 31, 2025 | -1.21 Mn |
| Sep 30, 2025 | 1.10 Mn |
| Sep 30, 2025 | 1.10 Mn |
| Jun 30, 2025 | 5.40 Mn |
| Jun 30, 2025 | 5.40 Mn |
| Mar 31, 2025 | -11.88 Mn |
| Mar 31, 2025 | -11.88 Mn |
| Dec 31, 2024 | -26.40 Mn |
| Dec 31, 2024 | -26.40 Mn |
| Sep 30, 2024 | -13.11 Mn |
| Sep 30, 2024 | -13.11 Mn |
| Jun 30, 2024 | -12.53 Mn |
| Jun 30, 2024 | -12.53 Mn |
| Mar 31, 2024 | -7.78 Mn |
| Mar 31, 2024 | -7.78 Mn |